Clicky

BioAtla, Inc.(BCAB)

Description: BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.


Keywords: Cancer Biopharmaceutical Clinical Medicine Drugs Health Care Tumor Monoclonal Antibodies Cancer Immunotherapy Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Hepatocellular Carcinoma Bladder Cancer Targeted Therapy Non Small Cell Lung Carcinoma Cervical Cancer Nsclc Gastric Cancer Renal Cell Carcinoma

Home Page: www.bioatla.com

BCAB Technical Analysis

11085 Torreyana Road
San Diego, CA 92121
United States
Phone: 858 558 0708


Officers

Name Title
Dr. Jay M. Short Ph.D. Co-Founder, CEO & Chairman
Mr. Scott Andrew Smith Pres & Director
Mr. Richard A. Waldron Chief Financial Officer
Dr. Eric L. Sievers M.D. Chief Medical Officer
Mr. Christian Vasquez VP of Fin., Corp. Controller & Sec.
Mr. Philippe Martin Chief Clinical Devel. & Operations
Lisa M. Pelton Accounting Mang.
Ms. Susie Melody Sr. VP of HR
Dr. Cathy Chang Ph.D. Sr. VP of R&D
Ms. Monica Sullivan Sr. VP of Intellectual Property & Contracts

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.5839
Price-to-Sales TTM: 989.2236
IPO Date: 2020-12-16
Fiscal Year End: December
Full Time Employees: 56
Back to stocks